Abstract
The use of VP-16 for stem cell mobilization has been cited as a significant risk factor for the development of therapy-related myelodysplasia/leukemia (tMDS/tAML) following autologous transplantation. The present study analyzed a large cohort of patients who underwent autotransplantation following stem cell mobilization with VP-16 and radiation-free preparation in order to determine the risk of tMDS/tAML. The estimated incidence of 9.9% at 7 years suggests that in the absence of TBI, VP-16 priming is not associated with an increased incidence of tMDS/tAML.
Publication types
-
Clinical Trial
-
Research Support, U.S. Gov't, P.H.S.
MeSH terms
-
Adolescent
-
Adult
-
Aged
-
Breast Neoplasms / complications
-
Breast Neoplasms / therapy
-
Etoposide / administration & dosage
-
Etoposide / toxicity*
-
Female
-
Hematopoietic Stem Cell Mobilization / adverse effects
-
Hematopoietic Stem Cell Mobilization / methods
-
Humans
-
Incidence
-
Leukemia / chemically induced*
-
Lymphoma / complications
-
Lymphoma / therapy
-
Male
-
Middle Aged
-
Neoplasms, Second Primary / chemically induced
-
Neural Tube Defects / chemically induced*
-
Peripheral Blood Stem Cell Transplantation / adverse effects
-
Peripheral Blood Stem Cell Transplantation / methods*
-
Probability
-
Transplantation, Autologous